HER2-Positive Breast Cancer - Pipeline Insight, 2026

DelveInsight's, "HER2-Positive Breast Cancer - Pipeline Insight, 2026" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in HER2-Positive Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

HER2-Positive Breast Cancer: Understanding

HER2-Positive Breast Cancer: Overview

HER2-Positive Breast Cancer is an aggressive subtype characterized by overexpression or amplification of the human epidermal growth factor receptor 2 (HER2), a protein involved in regulating cell growth and survival. It accounts for approximately 15-20% of all breast cancer cases and is associated with rapid tumor growth, higher recurrence rates, and poorer prognosis. HER2 overexpression activates key signaling pathways such as PI3K/AKT and MAPK, leading to uncontrolled cell proliferation and tumor progression. Diagnosis is typically confirmed using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).The cause of HER2-positive breast cancer is mainly linked to amplification of the HER2 gene, leading to overproduction of the HER2 protein and continuous activation of cell growth signals. According to the National Center for Biotechnology Information, this results in uncontrolled cell proliferation and tumor development. The condition is usually sporadic, caused by acquired genetic changes rather than inherited mutations, although factors like age and hormonal influences may contribute.

HER2-positive breast cancer may not present with noticeable symptoms in its early stages, similar to other types of breast cancer. When symptoms do occur, they commonly include changes in the size, shape, or contour of the breast, as well as the presence of a lump or mass, which may be small or pea-sized. Patients may also experience persistent thickening in the breast or underarm area, changes in the appearance or texture of the breast or nipple skin-such as dimpling, puckering, scaling, redness, or darkening-and the development of a hardened, marble-like area beneath the skin. In some cases, abnormal nipple discharge, including clear or blood-stained fluid, may also be observed. The treatment of HER2-positive breast cancer depends on factors such as disease stage and HER2 status, but it generally involves a combination of systemic and targeted approaches. Targeted therapies play a central role and include monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates (ADCs), which are designed to specifically recognize and attack HER2-expressing cancer cells while delivering cytotoxic agents directly to them. In addition, chemotherapy is often used either before surgery (neoadjuvant therapy) to reduce tumor size or after surgery (adjuvant therapy) to eliminate remaining cancer cells and lower the risk of recurrence.

"HER2-Positive Breast Cancer- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the HER2-Positive Breast Cancer pipeline landscape is provided which includes the disease overview and HER2-Positive Breast Cancer treatment guidelines. The assessment part of the report embraces, in depth HER2-Positive Breast Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2-Positive Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence HER2-Positive Breast Cancer R&D. The therapies under development are focused on novel approaches to treat/improve HER2-Positive Breast Cancer.

HER2-Positive Breast Cancer Emerging Drugs Chapters

This segment of the HER2-Positive Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

HER2-Positive Breast Cancer Emerging Drugs

• Trastuzumab pamirtecan (BNT-323) : BioNTech

Trastuzumab pamirtecan (BNT-323) is a third-generation topoisomerase-1 inhibitor-based ADC that specifically targets HER2. The drug is composed of a HER2-targeting antibody conjugated to a topoisomerase-1 inhibitor payload. This mechanism of action allows for the selective delivery of a cytotoxic agent to cancer cells expressing the HER2 protein, thereby minimizing systemic toxicity to healthy tissues. The efficacy of this targeted approach is particularly relevant for a clinical audience, as it offers a potential new treatment modality for a patient population that may have exhausted other standard-of-care options. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of HER2-Positive Breast Cancer.

• IBI354: Innovent Biologics

IBI354 is an innovative HER2-targeted antibody-drug conjugate developed using Innovent's proprietary SoloTx(R) ADC platform. Based on this platform, Innovent is promoting clinical trial studies multiple self-developed ADC molecules, which have shown promising safety and efficacy signals. With a drug-to-antibody ratio (DAR) of 8, IBI354 delivers a high payload of effective drugs to tumors. The highly hydrophilic linker design contributes to its excellent biophysical and pharmacokinetic (PK) properties, while the hydrophobic payload enhances its bystander effect, targeting adjacent antigen-low or negative tumor cells. IBI354 exhibits extremely low exposure of free toxin in circulation and has an ideal safety profile based on pre-clinical and clinical studies. IBI354 has demonstrated remarkable anti-tumor activity in various tumor-bearing mice models, particularly in those resistant to HER2-targeted therapies and in metastatic tumors Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of HER2-Positive Breast Cancer.

• BB-1701: Eisai Co., Ltd. / Bliss Biopharmaceutical (Hangzhou) Co., Ltd.

BB-1701 is a novel antibody-drug conjugate (ADC) designed to target and cause cytotoxicity to cancer cells that overexpress the HER2 protein. It is composed of an anti-HER2 antibody linked to a cytotoxic payload of eribulin, a synthetic analog of the marine macrolide halichondrin B. The conjugation of the eribulin payload to the antibody is achieved through a maleimido-PEG2-valine-citrulline-p-aminobenzylcarbamyl linker. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of HER2-Positive Breast Cancer.

• HLX22: Shanghai Henlius Biotech

HLX22 is a novel anti-HER2 monoclonal antibody that targets the HER2 extracellular subdomain IV. Its molecular design allows the agent to bind simultaneously to HER2 dimers on the surface of tumor cells. By promoting the internalization and degradation of these HER2 dimers, HLX22 enhances antitumor activity and addresses mechanisms of resistance that may limit the efficacy of existing HER2-targeted therapies. Currently, the drug is being evaluated in the Phase II/III stage of its development for the treatment of HER2-Positive Breast Cancer.

• ELVN-002: Enliven Therapeutics

ELVN-002, is a potent, highly selective, central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. The overexpression, amplification or mutation of HER2 is closely associated with aggressive forms of solid cancers, including breast cancer (BRC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and several others. ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities. Additionally, ELVN-002 is specifically designed to enable rational combination therapies, which will be important for the treatment of patients with metastatic HER2 overexpressing and amplified cancers. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of HER2-Positive Breast Cancer.

HER2-Positive Breast Cancer: Therapeutic Assessment

This segment of the report provides insights about the different HER2-Positive Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in HER2-Positive Breast Cancer

There are approx. 50+ key companies which are developing the therapies HER2-Positive Breast Cancer. The companies which have their HER2-Positive Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, BioNTech and others.

• Phases

DelveInsight's report covers around 55+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

HER2-Positive Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

HER2-Positive Breast Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses HER2-Positive Breast Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HER2-Positive Breast Cancer drugs.

HER2-Positive Breast Cancer Report Insights

• HER2-Positive Breast Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

HER2-Positive Breast Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing HER2-Positive Breast Cancer drugs?
• How many HER2-Positive Breast Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of HER2-Positive Breast Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the HER2-Positive Breast Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for HER2-Positive Breast Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• BioNTech
• Innovent Biologics
• Shanghai Henlius Biotech
• Eisai Co., Ltd.
• Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
• EMUXA Biotechnology
• CSPC ZhongQi Pharmaceutical Technology
• Johnson and Johnson
• Shanghai Henlius Biotech
• Novartis Pharmaceuticals
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Jiangsu HengRui Medicine Co., Ltd.
• Sichuan Baili Pharmaceutical Co., Ltd.
• Jazz Pharmaceuticals, Inc.
• Zymeworks Inc.
• Enliven Therapeutics
• Mersana Therapeutics
• Iambic Therapeutics, Inc.
• Alteogen, Inc.
• GeneQuantum Healthcare (Suzhou) Co., Ltd.

Key Products

• Trastuzumab pamirtecan
• IBI354
• HLX22
• BB-1701
• CCT303-406
• HB1801
• JNJ-0683 (ARX788)
• HLX87
• RG6596
• ECI830
• SHR-A1811
• BL M07D1
• Zanidatamab
• ELVN-002
• XMT-2056
• IAM1363
• ALT-P7
• GQ1001